Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
5.33
-0.37 (-6.49%)
At close: Apr 28, 2026, 4:00 PM EDT
5.25
-0.08 (-1.50%)
After-hours: Apr 28, 2026, 5:25 PM EDT

Cadrenal Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
9.356.753.552.52
Research & Development
4.14.214.080.43
Operating Expenses
13.4610.967.632.95
Operating Income
-13.46-10.96-7.63-2.95
Interest Expense
---0.02-0.12
Interest & Investment Income
0.220.310.250
Other Non Operating Income (Expenses)
---0.22-4.26
EBT Excluding Unusual Items
-13.24-10.65-7.62-7.32
Other Unusual Items
---0.74-
Pretax Income
-13.24-10.65-8.36-7.32
Net Income
-13.24-10.65-8.36-7.32
Net Income to Common
-13.24-10.65-8.36-7.32
Shares Outstanding (Basic)
2111
Shares Outstanding (Diluted)
2111
Shares Change (YoY)
63.48%35.59%70.99%-
EPS (Basic)
-6.64-8.73-9.29-13.92
EPS (Diluted)
-6.64-8.73-9.29-13.92
Free Cash Flow
-12.61-7.36-3.53-1.32
Free Cash Flow Per Share
-6.32-6.04-3.93-2.50
EBITDA
-13.45-10.96-7.63-2.95
D&A For EBITDA
0.01000
EBIT
-13.46-10.96-7.63-2.95
Source: S&P Capital IQ. Standard template. Financial Sources.